KUSUDAMA THERAPEUTICS SL
Company details
- Bankruptcy NIF/CIF: B75197350
-
-
-
-
Address: PQUE MIRAMON Nº196, (DONOSTIA-SAN SEBASTIAN) See in map
-
-
Featured products:
More information on KUSUDAMA THERAPEUTICS SL
-
28/06/2024 | BORME act no.: 291920 | Register: GIPUZKOASituación concursal
-
28/06/2024 | BORME act no.: 291920 | Register: GIPUZKOASituación concursal
-
26/08/2022 | BORME act no.: 393644 | Register: GIPUZKOAAmpliación de capital
-
27/02/2019 | BORME act no.: 92150 | Register: GIPUZKOAAmpliación de capital
-
12/07/2018 | BORME act no.: 290037 | Register: GIPUZKOAConstitución
-
12/07/2018 | BORME act no.: 290037 | Register: GIPUZKOADeclaración de unipersonalidad
-
12/07/2018 | BORME act no.: 290037 | Register: GIPUZKOACeses/Dimisiones
-
12/07/2018 | BORME act no.: 290037 | Register: GIPUZKOANombramientos
Other information
The CIF of KUSUDAMA THERAPEUTICS SL is B75197350, and its status in the business field is bankruptcy. The company's economic activity is classified under CNAE 2120 - Fabricación de especialidades farmacéuticas. Additionally, its SIC code - also identifies it. KUSUDAMA THERAPEUTICS SL has a team of Between 1 and 9 employees and records an annual turnover of less than 2 million euros. The company is registered in the Mercantile Registry of Gipuzkoa, with a total of 4 executive positions. The last announcement in Borme was published on 28/06/2024, and its last submission of ordinary annual accounts corresponds to the year 2021. To obtain contact information for KUSUDAMA THERAPEUTICS SL, such as phone number, address, or website, you can visit the Company Data module. If you wish to obtain more information about KUSUDAMA THERAPEUTICS SL, you can review some of our available financial reports, the company's Annual Accounts, or check its default incidents in the RAI delinquency file. The financial, business, and legal information provided for KUSUDAMA THERAPEUTICS SL comes from official sources and is up to date as of today.
Do you want to know more about KUSUDAMA THERAPEUTICS SL??
Find out more about this company by consulting these reports: